Table 2.

Safety of sorafenib in 2 randomized controlled trials.

	Sorafenib	Control
	(n = 143)	(n = 142)
Neutropenia	8.7%	4.8%
Thrombocytopenia	8.9%	4.3%
Skin toxicity	19.5%	6.3%
Infections	29.6%	28.0%
Gastrointestinal toxicity	25.2%	21.7%
Cardiac and renal insufficiency	11.8%	7.8%